Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Tremelimumab in Hypermutated Solid Tumors
NCT03911557Phase 2Completed
- Start
- Jun 2019
- Primary completion
- Oct 2025
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab and tremelimumab in solid tumor. Primary endpoint: Time-to-progression ratio at 2 years. Started Jun 2019; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03911557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03911557.